Moderna Announces First Participant Dosed In Phase 3 Study Of mRNA-1083, A Combination Vaccine Against Influenza And COVID-19
Portfolio Pulse from Benzinga Newsdesk
Moderna has announced that the first participant has been dosed in a Phase 3 study of mRNA-1083, a combination vaccine against Influenza and COVID-19.
October 24, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's Phase 3 study of mRNA-1083, a combination vaccine against Influenza and COVID-19, has begun with the first participant dosed. This could potentially boost Moderna's market position if the trial is successful.
The initiation of Phase 3 trials for Moderna's mRNA-1083 vaccine is a significant step towards its potential approval and market release. If successful, this could enhance Moderna's product portfolio and strengthen its market position, potentially leading to a positive impact on its stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100